Article Text

PDF
Systematic review and meta-analysis
Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma
  1. Neil C Thomson
  1. Institute of Infection, Immunity & Inflammation, University of Glasgow and Respiratory Medicine, Glasgow, UK
  1. Correspondence to: Professor Neil C Thomson, Institute of Infection, Immunity & Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, G12 OYN, UK; neil.thomson{at}glasgow.ac.uk

Statistics from Altmetric.com

Commentary on:

Context

Asthma is a common chronic disease that affects over 300 million people worldwide. Between 5% and 10% of this population has severe asthma, which often remains uncontrolled despite maximal conventional treatment. Omalizumab is a recombinant humanised monoclonal antibody that binds circulating IgE antibody and decreases allergic, IgE-mediated airway inflammation.1 In the USA and many other countries, omalizumab is approved for the treatment of adults and adolescents aged 12 years and above with moderate-to-severe persistent allergic asthma, whose symptoms are poorly controlled with inhaled corticosteroids (ICS). European approval stipulates that patients should have a history of frequent, severe exacerbations despite receiving ICS in high doses combined with an inhaled long-acting β2 agonist bronchodilator (LABA). The European license also includes children aged …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.